Half Year Results 

4D Pharma yet to take off

4D Pharma yet to take off

Shares in 4D Pharma (DDDD) were marked down following release of half-year results in which progress on the clinical front was tempered by an 18 per cent decline in net assets, coupled with an increased earnings loss. It has been a slow road towards commercialisation, so a 10 per cent increase in net operating cash outflow wouldn't have set any alarm bells ringing, but 4D is moving into a clinical trial phase that will place a major drain on its cash resources.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now